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Abstract Activation of jun N-terminal kinase (JNK)/stress-
activated protein kinase (SAPK) by interleukin-1 (IL-1) has been 
reported in many cells and in rabbit liver. Here we report 
selective activation of JNK/SAPK, without activation of p38 or 
p42 mitogen-activated protein kinases (MAPKs), by IL-1 in 
rabbit liver. We identified an IL-1 regulated JNK/SAPK 
activator present in rabbit liver using S Sepharose chromatog-
raphy. It was purified and immunoprecipitated by two antisera to 
MAP kinase kinase 7 (MKK7). It was not recognised by an 
antibody to MKK4. We conclude that MKK7 is the activator of 
JNK/SAPK activated by IL-1 in liver and that JNK/SAPK is the 
only MAPK activated by IL-1 in liver. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The mitogen-activated protein kinase (MAPK) cascades are 
intracellular signalling pathways which have been conserved 
from yeast to mammals. Activation of the MAPKs occurs by 
phosphorylation of threonyl and tyrosyl residues in a TXY 
motif by dual specificity MAPK kinases (MKKs). Three types 
of MAPKs are distinguished by the nature of the intervening 
amino acid. The first to be discovered, the p42 and p44 
MAPKs, contain a TEY motif and are activated by MKK1 
or MKK2, in response to mitogens and many other stimuli 
[1,2] including interleukin-1 (IL-1) in cultured connective tis-
sue cells [3-5]. The c-jun N-terminal kinases (JNKs), also 
called p54 MAPKs or stress-activated protein kinases 
(SAPKs) contain a TPY motif and are activated in response 
to cellular stresses and the pro-inflammatory cytokines IL-1 
and tumour necrosis factor (TNF) [6-8]. The p38 MAPKs 
contain a TGY motif and are usually activated by the same 
stimuli as JNK/SAPKs [9-13]. 
Three activators of the stress-activated kinases have been 
cloned: MKK3 [14] and MKK6 [15-18], which are specific for 
p38 MAPK, and MKK4/SEK1 [14,19] which can activate 
both p38 MAPK and JNK/SAPK but when overexpressed 
in cell lines preferentially activates the latter. It is unclear 
which of the MKKs is responsible for activation of MAPKs 
in tissues. 
*Corresponding author. Fax: +44 (181) 383-4499. 
Abbreviations: JNK/SAPK, jun N-terminal kinase/stress-activated 
protein kinase; GST, glutathione S-transferase; IL-1, interleukin-1; 
MAPK, mitogen-activated protein kinase; MKK, MAPK kinase; 
MKKK, MAPKK kinase 
IL-1 is able to activate all three types of MAPK in a variety 
of cells in culture [3,10,11] and we previously showed that it 
activates SAPKoc/JNK2 in rabbit liver [6]. We have now in-
vestigated its ability to activate the other MAPKs in the same 
tissue. In this tissue, p38 MAPK is constitutively active and is 
not regulated by IL-1. Instead, the cytokine selectively acti-
vates JNK/SAPK and we have provisionally identified the 
activator involved as the recently discovered MKK7 [20,21]. 
2. Materials and methods 
2.1. Materials 
Human IL-la was made as described [22]. [y-32P]ATP (Redivue) 
was from Amersham International (Slough, UK). Chromatography 
media and glutathione (GSH) Sepharose were from Pharmacia Bio-
tech (St. Alban's, Herts, UK). cDNA for histidine-tagged MAPK-
activated protein kinase-2 (MAPKAPK2) was a kind gift of M. Gaes-
tel (Max Delbrueck Center for Molecular Medicine, Berlin, Ger-
many). cDNAs for rat GST-SAPKp1 [7] and human GST-jun (amino 
acids 1-135), were kind gifts of J.R. Woodgett (Ontario Cancer In-
stitute, Toronto, Canada) and were expressed in E. coli. The proteins 
were purified by standard methods. Rabbit antiserum to p38 MAPK 
was to the synthetic peptide ISFVPPPLDQEEMES (amino acids 346-
360). Rabbit antisera to JNK/SAPK were to the synthetic peptide 
DSSLDASTGPLEGCR (amino acids 409^123 of SAPKcc), which 
was used for liver and to the synthetic peptide GVVKGQPSPSAQV-
QQ (amino acids 370-384 of SAPK(3) which was used for MRC-5. 
Rabbit antiserum to p42 MAPK was to the synthetic peptide EETA-
RFQPGYRS and was a gift from C. Marshall (ICR, Chester Beatty 
Laboratories, Fulham Rd, London). 
Rabbit antiserum 3936 was to GST fused with the C-terminal 128 
amino acids of MKK7. Rabbit antiserum 2125 was to a synthetic C-
terminal peptide of MKK7 (CRTSGVLSQHHLPFFR). 
2.2. Stimulation 
Female Dutch rabbits were sedated and injected via an ear vein 
with IL-la (5 Hg/kg) or vehicle. After 4 min a rapidly lethal anaes-
thetic was administered and the livers were removed and placed on 
ice: removal took about 4 min [6]. The livers were frozen in liquid 
nitrogen and stored at —70°C. Confluent MRC-5 fibroblasts (175 cm2 
flask per antiserum) were stimulated with 20 ng/ml IL-la for 15 min. 
2.3. Immunoprecipitation of MAPKs 
250 mg frozen liver was thawed and homogenised using a Polytron 
(Kinematica, Switzerland) in buffer A (20 mM HEPES pH 7.5, 20 
mM |3-glycerophosphate, 10 mM NaF, 0.1 mM Na3V04, 0.5 mM 
EDTA, 0.5 mM EGTA, 2 mM DTT)+0.2 M NaCl, 2 mM PMSF, 
10 uM E64, 10 mg/ml aprotinin. Homogenates were microfuged at 
16000Xg, 4°C for 15 min. To 1 mg of cleared homogenate, made up 
to 500 ul was added 500 ul of 2 X RIPA buffer (2 X buffer A including 
0.4 M NaCl 2% NP40, 1% DOC, 0.2% SDS) and 30 ul of protein A 
agarose coated with 5 ul of non-immune serum (NI) or 5 ul of one of 
the anti-MAPK antisera. Samples were shaken for 3 h at 4°C and the 
agarose beads were washed 4 times in RIPA buffer and twice in buffer 
A+10 mM MgCl2 before assay. 
MRC-5 fibroblasts were lysed in buffer B (20 mM Tris-acetate pH 
7.0, 0.1 mM EDTA, 1 mM EGTA, 10 mM P-glycerophosphate, 50 
mM NaF, 5 mM Na4P207, 0.27 M saccharose, 1% TRITON X-100, 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
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1 mM benzamidine, 0.1% (v/v) P-ME, 0.2 mM PMSF) and micro-
fuged at 16000Xg, 4°C for 15 min. MAPKs were immunoprecipitated 
as above. 
2.4. Assay of MAPKs 
To the protein A agarose beads from above was added 10 ul of 
substrate and 20 ul of assay buffer 1 (150 mM TRIS pH 7.4, 30 mM 
MgCl2, 60 uM ATP, 0.4 uCi/ul [y-
32P]ATP): substrate for p42 MAPK 
was myelin basic protein (MBP) at 100 ug/ml; substrate for p38 
MAPK was his-MAPKAPK-2 at 75 ug/ml and hsp27 at 50 ug/ml; 
substrate for JNK/SAPK was GST-jun (1-135) at 100 ug/ml. Samples 
were shaken for 20 min at 20°C, the assay was stopped and phos-
phorylated substrate was visualised by autoradiography of gels fol-
lowing SDS-PAGE. 
2.5. Lysis for chromatography 
Frozen livers were thawed and homogenised, using a Polytron (Kin-
ematica, Switzerland), in lysis buffer (20 mM TRIS pH 7.4, 50 mM 
NaF, 0.2 mM Na3V04 , 1 mM EDTA, 1 mM EGTA, 2 mM DTT)+l 
mM PMSF, 10 ug/ml aprotinin, 10 uM E64, 1 uM pepstatin. Five ml 
lysis buffer was used for each g of liver. Lysates were centrifuged at 
20000Xg, 4°C for 1 h, 1 M MES pH 6.0 was added to a final con-
centration of 20 mM and the sample was filtered (0.8 uM). 
2.6. Chromatography 
A 2 ml Fast Flow S Sepharose column was equilibrated in buffer C 
(20 mM MES pH 6.0, 20 mM P-glycerophosphate,10 mM NaF, 0.1 
mM Na3V04 , 0.5 mM EDTA, 0.5 mM EGTA, 2 mM DTT) at 4°C. 
Hundred mg of soluble protein was loaded onto the column. A 40 ml 
gradient of 0-1.2 M NaCl in buffer C was run. Two ml fractions were 
collected and assayed for activator of JNK/SAPK as described below. 
2.7. JNK/SAPK activator purification 
A 50 ml FFS Sepharose column (flow rate 60 cm/h) was equili-
brated in buffer C and approx. 5 g of liver cytosol protein was loaded. 
The column was washed in buffer C+0.3 M NaCl and the activity was 
eluted in buffer C+0.6 M NaCl. One M TRIS pH 8.5 was added to 
the eluate to a final concentration of 20 mM and pH 7.4. This was 
applied to a 10 ml phenyl Sepharose column (flow rate 60 cm/h) 
equilibrated in lysis buffer+0.6 M NaCl. The column was washed 
with lysis buffer and the active material was eluted in lysis buffer+1% 
CHAPS. One M TRIS pH 8.5 was added to 50 mM (final concen-
tration) and the sample was passed through a 1 ml Q Resource col-
umn equilibrated in buffer D (20 mM TRIS pH 8.5, 10 mM NaF, 20 
mM P-glycerophosphate, 0.2 mM Na3V04 , 0.5 mM EDTA, 0.5 mM 
EGTA, 2 mM DTT). The material passing through was dialysed over-
night at 4°C into buffer E (20 mM HEPES pH 7.5, 10 mM NaF, 0.1 
mM Na3V04 , 0.5 mM EDTA, 0.5 mM EGTA, 2 mM DTT, 0.05% 
BRIJ 35) and was loaded on a S Resource column equilibrated in 
buffer E at 4°C. This was eluted at 1 ml/min with a 20 ml gradient 
from 0 to 0.5 M NaCl in buffer E. One ml fractions were collected. 
2.8. JNK/SAPK activator assay 
Fifteen ul of sample was incubated with 5 ul of GST-SAPKp (100 
Ug/ml) and 10 ul of assay buffer 2 (150 mM TRIS pH 7.4, 30 mM 
MgCl2, 150 uM ATP) for 30 min at room temperature. Twenty ul of 
GSH Sepharose beads were added and the samples were shaken for 15 
min. The beads were given 3 X 1 ml washes in wash buffer (buffer 
Table 1 
Purification of IL-1 regulated activator of JNK/SAPK from rabbit liver 
E+0.2 M NaCl). Ten ul of wash buffer was added to the beads, along 
with 10 ul of GST-jun (100 ug/ml) and 10 ul of assay buffer 1 (150 
mM TRIS pH 7.4, 30 mM MgCl2, 60 uM ATP, 0.4 uCi/ul 
[y-32P]ATP). Samples were mixed for 20 min at room temperature, 
the assay was stopped and phosphorylated GST-jun was visualised by 
autoradiography following SDS-PAGE. 
2.9. Immunoprecipitation and assay for activator of JNK/SAPK 
Fifty ul of sample was added to protein A agarose coated with 3 ul 
of antiserum. The samples were mixed at 4°C for 4 h. The agarose 
beads were washed 5 X 1 ml with wash buffer (as above). At the last 
wash, the sample was split into two, for assay with and without GST-
SAPKp. To each pellet was added 10 ul wash buffer (±0.5 ug GST-
SAPKP) and 10 ul assay buffer 4 (150 mM TRIS pH 7.4, 30 mM 
MgCl2, 60 uM ATP). Samples were mixed for 1 h at room temper-
ature, 10 ul of assay buffer 5 was added (100 ug/ml GST-jun, 0.4 uCi/ 
Hi [y-32P]ATP), and the samples were shaken for another 20 min. The 
assay was stopped and phosphorylated GST-jun was visualised by 
autoradiography following SDS-PAGE. 
3. Results 
3.1. Activation of MAPKs in liver and in cultured cells by IL-1 
The activation of all three types of M A P K in rabbit liver 
following injection of IL-1 was measured by immunoprecipi-
tation of the enzymes and assay on appropriate substrates 
(Fig. 1A). J N K / S A P K was strongly activated, as expected, 
but p38 and p42 M A P K s were not, with the former showing 
constitutive activity. This was surprising in view of their acti-
vation in cultured cells (Fig. IB). We feel that it is unlikely 
that the kinetics of activation of p38 and p42 M A P K s may be 
different to those of J N K / S A P K in liver, since they are not 
different in cultured cells. 
3.2. IL-1 activates an activator of JNK/SAPK in liver 
We next assayed liver cytosols of IL-1- or vehicle-injected 
rabbits for an activator of J N K / S A P K by use of a rat re-
combinant SAPKP-GST fusion protein as substrate in a 
two-stage assay. Liver cytosol was incubated with the re-
combinant enzyme; the latter was then adsorbed to G S H 
Sepharose beads and its activity measured on GST-jun ( 1 -
135). Cytosol from the IL-1 treated animals activated the 
recombinant enzyme (Fig. 2A, lane 4), compared to cytosol 
from those treated with vehicle alone (Fig. 2A, lane 2). To 
show that hepatic J N K / S A P K is not carried over by the 
beads, GST-SAPKP was omitted from the procedure (Fig. 
2A, lanes 1 and 3). The untreated GST-SAPKp did not phos-
phorylate the GST-jun substrate (Fig. 2A, lane 6). 
To identify a putative activator on chromatography, cyto-
solic extracts were applied to a column of S Sepharose which 
was eluted with a salt gradient. The fractions were assayed for 
Control 
Cytosol 
Fast Flow S Sepharose 
Phenyl Sepharose 
Resource Q 
IL-1 
Cytosol 
Fast Flow S Sepharose 
Phenyl Sepharose 
Resource Q 
Resource S 
Protein (mg) 
6460 
92 
24 
7.4 
6290 
75 
22 
10 
5.15 
Total 
0 
2.7 
0.15 
0.13 
10 
6 
3.9 
2.7 
1.6 
activity (CPM) Specific activity (CPM/mg) Purification (fold) Yield (%) 
29 
6 
18 
l.( 
80 
177 
270 
311 
1 
50 
111 
170 
200 
100 
60 
39 
27 
16 
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an activator of JNK/SAPK as described for Fig. 2A. Frac-
tions from IL-1 treated animals showed increase in a peak of 
JNK/SAPK activator compared with controls. Activation in 
four experiments varied between two- and six-fold (Fig. 2B). 
3.3. Purification of the IL-1 stimulated activator ofJNKISAPK 
from liver 
Material from unstimulated and IL-1 stimulated rabbit liv-
ers was taken through three purification steps, so that the 
regulation by IL-1 could be confirmed. Table 1 shows that 
the overall recovery of activity after three steps of purification 
from IL-1 treated liver was 27%. Assay of equivalent fractions 
from control livers showed that IL-1 regulated material was 
being purified at each stage. The IL-1 regulated enzyme from 
Q Resource was next applied to a S Resource column and 
eluted by a salt gradient (Fig. 3A and Table 1). The enzyme 
did not elute sharply but over a wide conductivity range: 
there was little further increase in specific activity of the en-
zyme, which had been purified 200-fold. The single active 
peak was finally chromatographed on Superose 12: the acti-
vator eluted at a position corresponding to Mr 40 kDa, but 
the protein was not homogeneous on SDS-PAGE (data not 
shown). 
3.4. Identification of the activator as MKK7 
The activator was tested for its ability to react with anti-
bodies raised against known MKKs. Antisera to MKK3 and 
MKK4 did not immunoprecipitate or immunodeplete the ac-
tivator, nor did they stain any co-eluting antigen by Western 
blot (data not shown). However, two antisera raised against 
the recently discovered MKK7, which is activated by aniso-
mycin and hyperosmolar shock in NIH3T3 cells [21], immu-
noprecipitated the activator. Antiserum 2125 to a C-terminal 
synthetic peptide of MKK7 strongly precipitated activator 
from the fractions of S Resource chromatography, the fourth 
purification step (Fig. 3B). Antiserum 3936 to the C-terminal 
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Fig. 2. A: IL-1 activates an activator of JNK/SAPK in rabbit liver. 
Cytosolic extracts from vehicle- or IL-1-injected rabbits, or buffer 
alone, were incubated with (+) or without (-) GST-SAPKp" (17 ug/ 
ml) in assay buffer containing ATP (50 uM) for 30 min at room 
temperature. GSH Sepharose beads were added for 15 min with 
mixing. Beads were spun down, washed twice and incubated with 
GST-jun (1-135) and assay buffer containing [y-32P]ATP for 20 min 
at room temperature. Phosphorylated GST-jun (1-135) was detected 
by autoradiography, following SDS-PAGE. B: Cation exchange 
chromatography of hepatic activator of JNK/SAPK. Liver cytosol 
of control (open circle) or IL-1 stimulated (closed circle) rabbits was 
chromatographed on Fast Flow S Sepharose at pH 6.0 and eluted 
with a salt gradient. Fractions were assayed for activator of JNK/ 
SAPK as for B. Reaction mixtures were separated by SDS-PAGE 
and phosphorylation of GST-jun (1-135) was measured by Ceren-
kov counting. See Section 2 for details. Error bars show standard 
error of the mean. 
Fig. 1. A: IL-1 activates JNK/SAPK, but not p42 or p38 MAPKs 
in rabbit liver. Immunoprecipitates from 1 mg of liver lysate of ve-
hicle- or IL-1-injected rabbits were prepared with non-immune se-
rum (NI) or with antiserum (I) against the relevant kinase (see Sec-
tion 2). Immunoprecipitates were incubated with assay buffer 
containing [y-32P]ATP and the appropriate substrate: MBP for p42 
MAPK; GST-jun (1-135) for JNK/SAPK; his-MAPKAPK-2 and 
hsp27 for p38 MAPK; all three substrates for non-immune serum. 
Phosphorylated substrates were visualised by autoradiography fol-
lowing SDS-PAGE. B: IL-1 activates all three MAPK pathways in 
MRC-5 fibroblasts. Immunoprecipitates from unstimulated or IL-1 
stimulated MRC-5 cells were prepared using antisera against the rel-
evant kinase and were incubated with assay buffer and the relevant 
substrate as in A. Phosphorylated substrates were visualised by 
autoradiography following SDS-PAGE. 
128 amino acids also precipitated the activator (Fig. 3C). Nei-
ther non-immune nor pre-immune sera precipitated activity 
and no activated jun kinase was detected if recombinant 
GST-SAPK(3 was omitted. Both of these antisera recognised 
recombinant GST-MKK7 from E. coli upon Western blotting, 
but only faintly detected the putative hepatic MKK7 in frac-
tions from Superose 12 gel filtration, presumably due to a low 
concentration of antigen (data not shown). 
MKK7 was shown to activate JNK/SAPK preferentially, 
although it was able to activate p38 MAPK weakly in vitro. 
It did not activate p42 MAPK [20,21]. 
The hepatic JNK/SAPK activator did not phosphorylate 
p38 or p42 MAPKs, as judged by the inability of the peak 
fractions from S Resource chromatography (Fig. 3A) to phos-
phorylate GST-p38 or of the immunoprecipitates obtained 
with anti-MKK7 (Ab 3936) to phosphorylate GST-p38 or 
GST-p42 MAPKs (data not shown). 
4. Discussion 
Several laboratories, including our own, have reported that 
IL-1 activates all three types of MAPK in cultured cells. We 
felt it important to establish whether or not this also occurred 
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Fig. 3. A: Chromatography of JNK/SAPK activator on S Resource. Activator from Q Resource chromatography (Table 1) was applied to a S 
Resource column which was eluted with a salt gradient. Fractions were assayed for activator of JNK/SAPK as described for Fig. IB. (See Sec-
tion 2 for full details.) Absorbance units were obtained by densitometry of an autoradiograph. B: Antiserum 2125 to MKK7 immunoprecipi-
tates the JNK/SAPK activator. Pairs of active fractions from A were treated with protein A agarose coated with antiserum 2125 or pre-immune 
serum of 2125 and the beads were incubated with (+) or without (-) GST-SAPKp1 (25 ug/ml) in buffer containing ATP for 1 h at room tem-
perature. GST-jun and [y-32P]ATP were then added for a further 20 min. Phosphorylation of GST-jun (1-135) was detected by autoradiography 
after SDS-PAGE. C: Antiserum 3936 to MKK7 precipitates JNK/SAPK activator from a pool of fractions 2-13 from S Resource (Fig. 2A). 
in a tissue in vivo. We chose to investigate liver, which is a 
physiological target for the cytokine in the acute phase re-
sponse and in which we previously found striking activation 
of JNK2/SAPKoc, rapidly following injection of IL-1 [6]. As 
before, IL-1 activated JNK/SAPK, but it did not significantly 
activate p42 MAPK or p38 MAPK. Generally, stressful stim-
uli and IL-1 or TNF have been found to activate both JNK7 
SAPK and p38 MAPK together. Indeed they are commonly 
referred to as the stress kinases. However, selective p38 
MAPK activation has been reported in perfused heart sub-
jected to ischaemia [23] and selective JNK/SAPK activation 
has been reported in mouse liver exposed to metabolic oxida-
tive stress [24]. Our results suggest that IL-1 selectively acti-
vates JNK/SAPK in a differentiated tissue and that p38 
MAPK may not be involved in certain physiological responses 
to IL-1. The JNK/SAPK activation may be occurring in hep-
atic parenchymal cells and/or vascular endothelial cells. 
Whether or not such selective JNK/SAPK activation occurs 
in other tissues remains to be seen. The contrast with cultured 
cells suggests that in dedifferentiated proliferating cells, such 
as fibroblasts, new connections may be established between 
IL-1 receptors and MAPK pathways, perhaps to enable a 
broader spectrum of responses. 
We focussed on identifying the IL-1 stimulated activator of 
JNK/SAPK in rabbit liver, but were unable to purify it to 
homogeneity because it chromatographed broadly on cation 
exchange chromatography and did not bind to anion exchang-
ers. As judged by (a) immunoprecipitation, (b) its substrate 
preference and (c) its size on gel filtration, it was provisionally 
identified as MKK7. However, without knowing its amino 
acid sequence, we cannot be sure that it is not an unidentified 
relative of MKK7. It did not correspond to MKK4/SEK1, the 
only other well characterised activator of JNK/SAPK. We 
found no activator corresponding to MKK4/SEK1, but if 
this were a minor activator in liver, it could have been over-
looked. MKK4/SEK1 was found to be only a minor activator 
of JNK/SAPK in rat fibroblasts stressed by hyperosmolar 
shock [25]. 
MKK7 cDNA was originally isolated from a murine em-
bryo cDNA library during a yeast two-hybrid screen with 
human MKK1 as bait. Subsequently the enzyme was shown 
to interact with JNK/SAPK, but not with p38 or p42 
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M A P K s . It activated J N K / S A P K strongly and p38 M A P K 
weakly in vitro. It did not activate p42 M A P K [21]. Our 
results suggest that M K K 7 is the major activator mediating 
J N K / S A P K activation by IL-1 in liver. This may also be the 
case in other tissues since M K K 7 is widely expressed [21]. 
Several M K K kinases ( M K K K s ) are candidates for the 
activation of M K K 7 including M E K K 1 [26], M A P K K K 5 
[27], ASK1 [28], T A K 1 [29] and the mixed lineage kinases 
M L K 3 [30] and D L K [31]. It is at present unclear how specific 
these enzymes are for activation of JNK/SAPK. Many of 
them have also been shown to cause activation of p38 
M A P K upon overexpression in cells. However, some of these 
observations may be artefacts due to enzyme overexpression. 
Which, if any, of these M K K K s mediates the effects of IL-1 
remains to be established. 
During the preparation of this manuscript, SKK4, the hu-
man homologue of M K K 7 , was cloned and shown to be ac-
tivated by IL-1 in K B cells [32]. 
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